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The authors had previously mapped a new locus—DFNA17, for nonsyndromic hereditary hearing impairment—to
chromosome 22q12.2-q13.3. DFNA17 spans a 17- to 23-cM region, and MYH9, a nonmuscle–myosin heavy-chain
gene, is located within the linked region. Because of the importance of myosins in hearing, MYH9 was tested as
a candidate gene for DFNA17. Expression of MYH9 in the rat cochlea was confirmed using reverse transcrip-
tase–PCR and immunohistochemistry. MYH9 was immunolocalized in the organ of Corti, the subcentral region of
the spiral ligament, and the Reissner membrane. Sequence analysis of MYH9 in a family with DFNA17 identified,
at nucleotide 2114, a GrA transposition that cosegregated with the inherited autosomal dominant hearing im-
pairment. This missense mutation changes codon 705 from an invariant arginine (R) to histidine (H), R705H,
within a highly conserved SH1 linker region. Previous studies have shown that modification of amino acid residues
within the SH1 helix causes dysfunction of the ATPase activity of the motor domain in myosin II. Both the precise
role of MYH9 in the cochlea and the mechanism by which the R705H mutation leads to the DFNA17 phenotype
(progressive hearing impairment and cochleosaccular degeneration) remain to be elucidated.
Introduction
We had previously mapped a new locus for nonsyndromic
hereditary hearing impairment (HHI), DFNA17 (MIM
603622), to chromosome 22q12.2-q13.3.DFNA17maps
to a relatively large genetic region of 17–23 cM, typical
for the size of the family studied (Lalwani et al. 1999).
The low resolution of the linked region precluded the use
of the positional-cloning approach to identify the disease
gene. The candidate-gene approach, the default alterna-
tive to positional cloning, was therefore pursued (Collins
1995). Analysis of the chromosome 22 gene map iden-
tified 163 candidate genes within the region spanning the
DFNA17 locus (Dunham et al. 1999). One of the can-
didate genes encoding the nonmuscle–myosinheavy-chain
A (MYH9) was selected for further analysis. The selection
of MYH9 (which encodes a member of the class II, or
conventional, myosins) was based on identification of mu-
tations in several other myosin heavy-chain genes that are
pathogenically linked to HHI (Friedman et al. 1999).
The class II myosins are broadly expressed in skeletal,
cardiac, and smooth muscles, as well as in nonmuscle
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tissues, and they consist of a pair of heavy chains, a
pair of light chains, and a pair of regulatory light chains
(Sellers 2000). The N-terminal motor domain is the
most highly conserved region of the myosin heavy chain
and contains the ATP- and actin-binding sites. The my-
osin, also known as the “sarcomeric myosin,” that me-
diates skeletal muscle contraction represents the most
well-characterized representative of the class II myosin
family. Cardiac muscle cells and smooth muscle cells
also possess isoforms of class II myosin that are distinct
from the sarcomeric myosin and that mediate contrac-
tion in these muscle cells.
Characterization of myosins in the nonmuscle cells
has identified two distinct isoforms of class II myosin:
nonmuscle myosin–IIA (MYH9) (Saez et al. 1990; Si-
mons et al. 1991) and nonmuscle myosin–IIB (MYH10)
(Simons et al. 1991). MYH9 and MYH10 have been
mapped to 22q11.2 and 17q13, respectively, and exhibit
85% identity in their motor domains. Several skeletal
muscle heavy-chain genes have also been localized to
the region containing MYH10. Most cells express rela-
tively equal amounts of each of these myosins, with a
few exceptions. For example, platelets express MYH9
only (Maupin et al. 1994; Phillips et al. 1995), whereas
neuronal tissues predominantly express MYH10.
MYH9 and MYH10 demonstrate overlapping but dis-
tinct intracellular locations when coexpressed within
the same cell type (Kolega 1998a, 1998b). In vitro mo-
tility studies of these two isoforms have shown that
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MYH9 is severalfold faster than MYH10, both in its
rate of ATP hydrolysis and in its rate of movement of
actin filaments (Kelley et al. 1996). The differences in
their localization and in their in vitro characteristics
suggest differing in vivo functions.
Our understanding of the biological role of nonmus-
cle myosin is derived in part from studies in invertebrate
animals and by analogy with skeletal and smooth mus-
cle myosin II. Use of invertebrate model systems has
shown that nonmuscle myosin II is directly involved in
diverse cellular functions, including the mediation of
cytokinesis in Dictyostelium species (De Lozanne and
Spudich 1987), the morphogenesis during the devel-
opment of Drosophila species (Edwards and Kiehart
1996), and the establishment of cellular polarity in Cae-
norhabditis elegans embryos (Guo and Kemphues
1996). In vertebrate animals, the biological role of
MYH10 has been investigated through the generation
of knockout mice (Tullio et al. 1997). The MYH10/
fetuses die in utero or perinatally because of congestive
heart failure, demonstrating that MYH10 is required
for normal cardiac development. The biological role of
MYH9 has not yet been investigated or described in
vertebrates.
In the present study, we have identified an MYH9
mutation that is linked to nonsyndromic deafness and
is known as “DFNA17.” The mutation, R705H, the
consequence of a GrA transposition in the nucleotide
sequence, is considered critical for the ATPase activity
of the myosin motor domain. The cosegregation of the
mutant MYH9 with nonsyndromic hearing impairment
demonstrates a biologically significant role for MYH9
in hearing and an organ-specific pathology associated
with the mutant allele.
Family, Material, and Methods
Family Data
The family has been described in detail elsewhere (Lal-
wani et al. 1997, 1999). In brief, affected family mem-
bers exhibit nonsyndromic HHI with an autosomal
dominant mode of transmission. The hearing impair-
ment begins at age 10 years and initially involves only
the high frequencies; by the third decade of life, affected
family members have moderate-to-severe deafness. His-
tological examination of the proband’s temporal bone
revealed classical cochleosaccular dysplasia (CSD) with
degeneration of the organ of Corti, the saccular epithe-
lium, and the stria vascularis. In addition, the proband
had asymptomatic loss of neurons, and gliosis was pres-
ent in the inferior olivary nucleus. The deafness in the
family was mapped, by linkage analysis, to 22q12.2-
22q13.3, a region spanning 17–23 cM.
Reverse Transcriptase–PCR Assay of MYH9 Expression
in the Rat Cochlea
One microgram of total RNA from rat kidney, lung,
and cochlea was extracted and then reverse transcribed
into cDNA by use of MMLV (Moloney murine leukemia
virus) reverse transcriptase (RT) (Life Technologies) and
random hexamers. The reaction was heat inactivated,
and 1 ml of a total volume of 20 ml was used in the PCR
to assay, by rat MYH9–specific primers, for the presence
of MYH9 expression. The primers were designed using
Primer3 software and the rat MYH9 sequence (GenBank
accession number GI 6981235). PCR was carried out in
a PTC-200 thermocycler (MJ Research) in a total volume
of 20 ml with 1.5 mM MgCl2, 200 mM dNTP, 5 pmol
each of forward and reverse primers, and a unit of Taq
DNA polymerase. An initial denaturing period of 3 min
at 94C was followed by 35 cycles of 15 s at 94C, 20
s at 55C, and 30 s at 72C and by a final extension
period of 5 min at 72C. The PCR products from two
sets of primer pairs—MYH9(2163)A (ggagttccggca-
gaggtatgag) and MYH9(2994)B (cttggccagtttgcag-
ttttga) and MYH9(2504)A (ggctcttcaccaaggtcaag) and
MYH9(3201)B (gctgaggtctgtggagtctc)—were sequenced
to assess their identity. The MYH9 primer pairs delimit
a region of 11 kb midway across the MYH9 cDNA se-
quence. To confirm the integrity of cDNA, the tissue
cDNA was also characterized for expression of a house-
keeping gene, cytochrome p450 reductase (CYPR), by
CYPR-specific primers CYPR(1141)A (ccgcacggccctcac-
ctacta) and CYPR(1511)B (tggccacccccttgttcactc).
Immunodetection of MYH9 in the Rat Cochlea
The rat cochlea was harvested, decalcified, and em-
bedded, as described elsewhere (Mhatre et al. 1999). The
paraffin-embedded tissues were sectioned (6 mm) and
mounted on Superfrost-pretreated glass slides (Fisher
Scientific). Cochlear sections were deparaffinized, re-
hydrated, and then incubated with a blocking reagent,
I-PBT (0.2% I-block [Tropix] and 0.05% Tween-20 in
PBS). The blocked sections were incubated in the pres-
ence or absence of varying dilutions (1:25–1:200) of a
polyclonal anti-MYH9 antibody (Biomedical Technol-
ogies). The anti-MYH9 antibody is prepared in rabbits,
from human platelet myosin, and is not cross-reactive
with any other protein, including myosins of skeletal,
smooth, and cardiac muscle). The tissue sections were
washed with PBS and incubated with a biotin-conju-
gated anti–rabbit IgG secondary antibody (Vector Lab-
oratories) at a dilution of 1:250 in I-PBT for 1 h at room
temperature. The bound label (biotin) was amplified
with alkaline phosphatase–conjugated streptavidin di-
luted to 1:500 in I-PBT for 1 h at room temperature.
The bound label was detected using NBT-BCIP, an al-
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Figure 1 RT-PCR analysis of MYH9 expression in rat cochlear
cDNA. cDNA from several tissues, including the cochlea, was assayed
for MYH9 expression via PCR using MYH9-specific primers. A,
cDNA from the cochlea, kidney, and lung. All samples yielded the
expected 698-bp fragment amplified using rat MYH9-specific primers.
Cochlear RNA, in the absence of RT, and water (H2O) served as
negative controls. B, cDNA from all tissues tested for MYH9 expres-
sion. All samples are positive for expression of CYPR, a housekeeping
gene, using CYPR-specific primers that yield the expected 371-bp
fragment.
kaline phosphatase color substrate, and the slides were
coverslipped for microscopy.
Mutation Analysis of MYH9 in the Family with
DFNA17
cDNA analysis.—The MYH9 transcript of affected
(III-4) and unaffected (V-2) members of the family with
DFNA17 was detected and characterized using total
RNA harvested from Epstein-Barr virus–transformed
lymphocytes. One microgram of the total RNA was re-
verse transcribed into cDNA, by MMLV RT (Life Tech-
nologies) and random hexamers. The cDNA was am-
plified with human MYH9–specific primer sets that
yielded overlapping fragments spanning the entire length
of the MYH9 coding sequence (5,886 bp). The amplified
fragments were purified and then sequenced bidirection-
ally, by an ABI automated sequencer (Applied Biosys-
tems) with appropriate primers. Sequencher software
(Gene Codes) was used for sequence analysis.
Genomic analysis.—The 40 exons, including the in-
tron-exon junctions, of MYH9 were directly assessed
using DNA harvested from the peripheral blood leuko-
cytes of individuals III-4 and V-2. Approximately 50 ng
of genomic DNA was amplified with MYH9-specific
primer pairs for each of the 40 MYH9 exons (Dunham
et al. 1999), and the amplified products were sequenced
using an ABI automated sequencer. Sequencher software
was used for sequence analysis. After the presence of a
mutation in exon 16 was established, this exon was
amplified from all members of the family with DFNA17
and was sequenced using primer pairs MYH9-16F1
(tgttctaggcacggaagtgag) and MYH9-16R1 (ttctacatg-
gatggaggacg) or MYH9-16F2 (tcttgccctgtcaggttcat) and
MYH9-16R2 (agcccacctctgggactc). The MYH9-16F1/
R1 and MYH9-16F2/R2 primer pairs yielded a 295- and
a 284-bp fragment, respectively.
Restriction analysis.—Mutation detection by sequence
analysis was corroborated through restriction-enzyme
analysis. MYH9 exon 16 was PCR-amplified from ge-
nomic DNA of the members of the family with DFNA17
and from 50 control individuals with normal hearing.
The amplified product was digested with the restriction
enzyme Fnu4HI at 37C for 1 h and was then resolved
on a 10% acrylamide gel. The mutant sequence alter-
ation eliminates an Fnu4HI restriction site in MYH9
exon 16 of the affected individuals, thereby yielding
a restriction-digestion pattern different from that of un-
affected individuals.
Results
Expression Analysis of MYH9 in the Rat Cochlea
Tissue samples of rat kidney, lung, and cochlea were
screened for expression of MYH9 transcript. The primer
pair MYH9(2504)A and MYH9(3201)B (see Family,
Material, and Methods section) was used to amplify a
698-bp DNA from kidney, lung, and cochlear cDNA
(fig. 1A). A similar tissue-expression pattern was also
found, by primers MYH9(2163)A and MYH9(3201)B
to amplify adjacent MYH9 coding sequence (data not
shown). cDNA from all three tissue types was positive
for CYPR expression, confirming the integrity of the
cDNA (fig. 1B). Fragments from the cochlea that were
PCR-amplified using MYH9-specific primers were se-
quenced and were found to be nearly identical with the
rat MYH9 sequence published elsewhere (GenBank ac-
cession number GI 6981235). The nucleotide sequence
of the amplified PCR fragments, spanning 11 kb of cod-
ing region, contained four single-base-pair differences in
four separate codons from the published sequence of rat
MYH9. Three of these substitutions are silent changes.
The fourth, a GrA transposition at nucleotide 3019,
which represents the first base in codon 1007, changes
the amino acid from aspartate (D) to leucine (N); N is
also present at codon 1007 in human MYH9. The
D3019N alteration is considered to be a polymorphism.
MYH9 was immunolocalized in cochlear sections
with a polyclonal anti-MYH9 antibody prepared against
purified platelet myosin (Biomedical Technologies). The
MYH9 immunoreactivity was detected in various coch-
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Figure 2 Immunolocalization of MYH9 in the rat cochlea. Radial sections of the rat cochlea were hybridized with anti-MYH9 antibody,
were developed with a biotinylated, alkaline phosphatase–linked amplification system and were stained with NBT-BCIP. A, Photomicrograph
of rat cochlear duct, illustrating the presence of anti-MYH9 immunoreactivity in several regions of the cochlea, including outer hair cells, cells
of the organ of Corti (OC), the subcentral region of the spiral ligament (SL), and the Reissner membrane (RM). SGNp spiral ganglion neurons;
SV p stria vascularis. B, The cochlear sections incubated without the anti-MYH9 antibody. The sections are free of immunoreactivity.
lear tissues (fig. 2A); these included outer hair cells in
the organ of Corti, the subcentral region of the spiral
ligament, and the Reissner membrane. MYH9 was not
observed in the auditory neurons or within the stria vas-
cularis, a vascular tissue that forms the lateral wall of
the cochlear duct. Despite the presence of MYH9 in the
auditory neuroepithelia, MYH9 immunoreactivity was
absent in the cupular vestibular neuroepithelia.
Analysis of MYH9 in the Family with DFNA17
Sequence analysis of MYH9 in the family with
DFNA17 was undertaken after demonstration that its
transcript and the translated product were present in the
inner ear of the rat cochlea. The MYH9 was initially
screened by sequence analysis of its cDNA, prepared
from reverse-transcribed RNA harvested from periph-
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eral blood lymphocytes of the affected and unaffected
members of the DFNA17 pedigree shown in figure 3A.
The sequence from an affected member (III-4) contained
a single-base-pair heterozygosity at two locations (nu-
cleotides 2114 and 4902) within the coding sequence, a
heterozygosity that was absent in the MYH9 cDNA se-
quence of an unaffected member (V-2). The GrA trans-
position at nucleotide 4902, at the third position of co-
don 1634, is a silent base-pair alteration, because it does
not change the amino acid at this site. The second of
these two differences resulted in an altered MYH9 poly-
peptide. This sequence alteration was observed at nu-
cleotide 2114, representing the second nucleotide in co-
don 705. Although the unaffected individuals displayed
G at nucleotide 2114, the affected individuals displayed
both G and A. The presence of A at nucleotide 2114
alters codon 705, causing substitution of arginine by
histidine. The amino acid substitution caused by this
single-base-pair transposition is located within exon 16
of the MYH9 gene.
Sequence analysis of all 40 coding exons of theMYH9
gene from the genomic DNA harvested from represen-
tative members of the family with DFNA17 confirmed
the presence of the GrA transposition in exon 16 of the
affected members but not in the unaffected members (fig.
3B). The GrA transposition in the second nucleotide of
codon 705 causes the elimination of Fnu4HI restriction
site. Therefore, the Fnu4HI digest of exon 16 amplified
from affected individuals is expected to yield an addi-
tional restriction fragment, of 149 bp, that is not seen
in unaffected individuals. This marker was used to cor-
roborate the presence of the sequence alteration within
exon 16 of MYH9 in the affected members—as well as
its absence in the unaffected members—of the family
with DFNA17 (fig. 3C). Individuals V-1 and V-3, whose
affected status was unknown because of their young age
at the time of linkage analysis, were found to be unaf-
fected and affected, respectively, by sequence and re-
striction analysis. The GrA transposition in nucleotide
2114 was absent in the genomic DNA from 50 randomly
selected healthy individuals. Sequence alignment of the
MYH9 polypeptide spanning the SH1-SH2 linker region
of muscle and nonmuscle class II myosins from seven
species illustrates both the strict conservation of this
linker region and the invariance of arginine (R705) in
this sequence motif (fig. 4).
Discussion
Through the use of the candidate-gene approach, we
have identified MYH9 as the gene at the DFNA17 locus
that is responsible for autosomal dominant HHI.MYH9
represents the first conventional myosin heavy-chain
gene linked to hearing impairment, and it joins the grow-
ing list of unconventional (non–class II) myosin heavy-
chain genes (myosins VI [Avraham et al. 1995], VIIA
[Gibson et al. 1995, Weil et al. 1995], and XV [Probst
et al. 1998]) associated with HHI. Similar to MYH9,
expression of these unconventional myosins is not lim-
ited to the cells and tissues of the inner ear, yet the pre-
dominant clinical manifestation of their dysfunction is
hearing impairment.
The identified mutation, R705H, occurs in a highly
conserved and functionally critical region within the
carboxy-terminal half of the myosin heavy-chain motor
domain that forms the globular head in the hexameric
myosin molecule. Within the motor domain, R705 re-
sides in a highly conserved linker region that spans 16
amino acids and that contains two free thiol groups,
C704 (SH1) and C694 (SH2). Crystal structure of the
globular head of skeletal muscle myosin has shown that
the two thiols are part of two short a-helices joined
through a kink at the conserved G696 residue (Rayment
1996; Gulick and Rayment 1997). The SH1 and SH2
helices are believed to play a key role in the confor-
mational changes that occur in the myosin head during
force generation coupled to ATP hydrolysis. X-ray crys-
tallographic studies suggest that during the power
stroke the light-chain–binding domain swings relative
to the catalytic/ATP-binding domain. The pivot point
of this swinging motion is considered to be in the vi-
cinity of the SH1-SH2 helix (Houdusse et al. 1999).
Not surprisingly, in vitro and in vivo modification of
the SH1 helix, including cross-linking of SH1-SH2
groups or alteration/substitution of SH1/SH2, has been
shown to disrupt the mechanical function of the myosin
motor domain (Patterson et al. 1997; Suzuki et al.
1997). These studies have demonstrated that the func-
tional integrity of myosin is critically dependent on its
flexibility at the SH1-SH2 helix. The strict conservation
of this linker region among myosin II subtypes within
and between species further underscores its functional
importance. The R705H mutation in the family with
DFNA17 may cause an altered conformation of the
SH1 helix that affects its flexibility and movement, there-
by disrupting the mechanical function of the motor
domain.
We have not yet determined the mechanism by which
MYH9 dysfunction leads to hearing loss and the ob-
served inner-ear histopathology, i.e., CSD, in the pro-
band with DFNA17. Localization of MYH9 expression
in the mammalian cochlea has particular importance
for understanding and interpreting the histopathology
associated with its dysfunction. Within the rat cochlea,
MYH9 expression was localized in three distinct tissue
types: the organ of Corti, the subcentral region of the
spiral ligament, and the Reissner membrane. Within the
organ of Corti, the MYH9 expression was identified
Figure 3 A, Pedigree with DFNA17. The affected members of five generations of the family with DFNA17 are denoted by blackened
symbols. B, Sequence analysis of MYH9 in the family with DFNA17. MYH9 was sequenced in genomic DNA from the affected and unaffected
members of the family with DFNA17. Although a single peak (G) is observed at nucleotide 2114 in the MYH9 sequence from the unaffected
member V-2 (upper panel), a doublet (A/G) is observed at nucleotide 2114 (N) in the affected member III-4 (lower panel). The GrA transposition
alters the codon from arginine (R) to histidine (H). C, Restriction analysis of MYH9 exon 16 2114GrA mutation eliminates the Fnu4HI
restriction site, and this is reflected in the restriction digest pattern of MYH9 exon 16 from affected (III-4) and unaffected (V-2) individuals
from the DFNA17 pedigree. The 284-bp PCR-amplified fragment contains three recognition sites for Fnu4HI—at 130, 135 and 168 bp from
the 5′ end, of which the last site is absent in the mutant allele. Numbers at left are sizes of DNA ladder bands.
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Figure 4 Alignment of the SH1 linker region in class II myosins.
Alignment of peptide sequence spanning the SH1 linker region of mus-
cle and nonmuscle class II myosins from seven species illustrates both
the strict conservation of this linker region and the invariance of ar-
ginine (R705) in this sequence motif.
throughout the outer hair cells, including those of the
cuticular plate. Both myosin VI and myosin VIIA have
also been localized within the mechanosensory hair
cells. Myosin VI is localized within the actin-rich cutic-
ular plate and in the rootlet actin filaments that descend
from stereocilia into the cuticular plate, suggesting a
role in stabilizing the basal attachment of stereocilia
(Avraham et al. 1997, Hasson et al. 1997). Myosin VIIA
is localized in the stereocilia and cell body of hair cells
(Hasson et al. 1997). Postulated roles for myosin VIIA
include the maintenance of stereocilia integrity and
membrane trafficking in the inner hair cells. The role
of MYH9 in hair cells remains to be deciphered.
MYH9 expression was also identified in the Reissner
membrane, a membranous barrier consisting of two lay-
ers of cells that forms the upper boundary of the coch-
lear duct. The CSD histopathology of the proband af-
fected with DFNA17 demonstrated a collapsed Reissner
membrane (Lalwani et al. 1997). MYH9 dysfunction
in the Reissner membrane may contribute to its com-
promised cytoarchitecture, thus disturbing cochlear-
fluid homeostasis and effecting cochlear function. Of
the various cochlear tissues, the one with the most con-
spicuous absence of MYH9 expression is the stria vas-
cularis, which forms the lateral wall of the cochlear duct
and whose dysfunction is generally considered to be the
cause of CSD. The absence of MYH9 expression in the
stria vascularis suggests that this tissue type is not di-
rectly responsible for the underlying pathophysiology
of CSD.
MYH9 is also expressed within the spiral ligament
that consists of connective tissue comprising fibrocytes.
These fibrocytes of the spiral ligament are classified ac-
cording to the distinct isoforms of the Na and K ATP-
ase that they express, as well as by their cytoskeletal
components. The subcentric region of the spiral liga-
ment, which is immnoreactive to the MYH9 antibody,
is characterized by the presence of type III and type IV
fibrocytes. The type III fibrocytes are rich in actin and
other contractile and contraction-associated proteins
(Henson et al. 1984, 1985). The postulated role for
these cells includes providing anchorage for surround-
ing cells and/or developing or reacting to tension gen-
erated in the basilar membrane–spiral ligament complex
(Henson et al. 1985). Maintenance of this tension is
probably more crucial in the basal turn of the cochlea,
where sensitivity to high frequencies resides and where
the basilar membrane is wider than at the apex. This
may be the simple explanation for the observed high-
frequency hearing impairment in DFNA17. The con-
tribution of MYH9 dysfunction to HHI and presbycusis
(age-associated hearing impairment similar to the
DFNA17 phenotype) remains to be determined. Both
the precise role of MYH9 in the cochlea and the mech-
anism by which R705H mutation leads to the DFNA17
phenotype of progressive hearing impairment and CSD
remain to be elucidated.
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